Loading clinical trials...
Loading clinical trials...
Phase IB Study of Atezolizumab and Bevacizumab With SBRT for Unresectable Hepatocellular Carcinoma
Conditions
Interventions
Atezolizumab
Bevacizumab
+1 more
Locations
3
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
August 23, 2022
Primary Completion Date
January 31, 2027
Completion Date
January 31, 2032
Last Updated
February 18, 2026
NCT07175441
NCT07141056
NCT06911255
NCT06788353
NCT06593964
NCT07480382
Lead Sponsor
Massachusetts General Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions